News

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer.

Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With a deep background in working across multiple therapeutic areas and successfully leading organizations through regulatory approvals, Dr. Matkovits will play a critical role in Kaléo’s continued expansion and development of the company’s innovative Aerio™ Auto-Injector Platform. Her appointment comes at an exciting time for Kaléo, which recently secured key contracts with the U.S. Department of Defense and the Department of Health and Human Services, further strengthening the company’s role in providing medical countermeasures.

“Theresa’s extensive experience in leading global drug development and commercialization will be a key asset as we continue to leverage our innovative product portfolio to expand our medical countermeasures business,” said Michael Wells, Chairman and Chief Executive Officer of Kaléo. “Her proven ability to navigate regulatory landscapes and drive operational excellence makes her an outstanding addition to our executive team.”

Prior to joining Kaléo, Dr. Matkovits served as Chief Development Officer for Matinas Biopharma, where she led the company’s clinical-stage asset and secured strategic partnerships with key organizations such as the NIH and the Cystic Fibrosis Foundation. Throughout her extensive career, she has held leadership positions at NPS Pharmaceuticals, The Medicines Company, and Novartis, making significant contributions to drug development, regulatory advocacy, and commercialization efforts.

Read more here.

Recent News

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals

04/22/2025

ATCC Announces New Executive Leadership Appointments

ATCC, the world’s premier biological materials management and standards organization, today announced several new leadership appointments. Rebecca Bradford, MBA, has been promoted to the role of senior vice president of Government Programs, ATCC Federal Solutions (AFS); Manoj Menon, PhD, has joined the company as chief operating officer; and Rupali Lach was appointed vice president of Commercial Operations.